Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Cash & Equivalents: 2018-2024

Historic Cash & Equivalents for CureVac N.V (CVAC) over the last 7 years, with Dec 2024 value amounting to $514.8 million.

  • CureVac N.V's Cash & Equivalents rose 103.83% to $444.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $444.5 million, marking a year-over-year increase of 103.83%. This contributed to the annual value of $514.8 million for FY2024, which is 18.89% up from last year.
  • Per CureVac N.V's latest filing, its Cash & Equivalents stood at $514.8 million for FY2024, which was up 18.89% from $433.0 million recorded in FY2023.
  • In the past 5 years, CureVac N.V's Cash & Equivalents registered a high of $1.6 billion during FY2020, and its lowest value of $433.0 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $484.5 million, with a median of $505.8 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 4,542.93% in 2020, then slumped by 45.51% in 2022.
  • Over the past 5 years, CureVac N.V's Cash & Equivalents (Yearly) stood at $1.6 billion in 2020, then plummeted by 41.13% to $928.3 million in 2021, then plummeted by 45.51% to $505.8 million in 2022, then decreased by 14.40% to $433.0 million in 2023, then increased by 18.89% to $514.8 million in 2024.